It should be safety-first on stem cell therapies
By Editorial,
The Boston Globe
| 02. 12. 2016
Untitled Document
As interest in alternative medicines has risen, so has the number of clinics pushing the supposed benefits of stem cell therapies. These businesses say stem cells have the power to help the body repair itself, without surgery or painful side effects. They’re using them to treat everything from cosmetic “flaws” (sagging skin and hair loss) to life-changing ailments (Parkinson’s disease and diabetes). The clinics’ pitches are carefully crafted to hype potentially dramatic results, without running afoul of federal regulators. A “rejuvenation center” in Arizona sells a treatment that will “improve your marriage.” A Florida stem cell company advertises “groundbreaking advances” that give patients “the ability to fight back against diseases once thought untreatable.” And a California outfit claims its customers have reported “higher energy levels, better sleep, and overall improved quality of life.”
It all sounds appealing, maybe even borderline miraculous, but the safety and effectiveness of such services is, at best, questionable. Until now, stem cell clinics have faced only minimal scrutiny from the Food and Drug Administration. Unlike drugs and medical devices, stem cell...
Related Articles
By Carly Mallenbaum, Axios [cites Emily Galpern] | 03.29.2026
More Americans are turning to surrogacy to build their families, as the practice becomes more common and more publicly discussed.
Why it matters: As surrogacy becomes more visible and accessible, ethical, legal and cultural tensions become harder to ignore...
By Carly Mallenbaum, Axios [cites Surrogacy360] | 03.29.2026
Without a federal law, surrogacy in the U.S. is governed by a patchwork of state regulations/
Why it matters: Confusing, varied local rules can determine everything from whether agreements are legally binding to who is recognized as a parent at...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...